Travere Therapeutics (NASDAQ:TVTX) Insider Sells $283,816.55 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 6,785 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $41.83, for a total value of $283,816.55. Following the completion of the transaction, the insider directly owned 105,211 shares in the company, valued at approximately $4,400,976.13. This trade represents a 6.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $40.77 on Friday. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $43.31. The business’s fifty day simple moving average is $29.99 and its 200-day simple moving average is $31.54. The firm has a market cap of $3.77 billion, a PE ratio of -135.90 and a beta of 0.86. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s addressable U.S. patient population and underpinning multi‑year revenue upside. Filspari approval article
• Positive Sentiment: Multiple brokerages raised ratings and price targets (examples cited include Canaccord, Guggenheim, Piper Sandler and HC Wainwright), reinforcing bullish revenue and valuation revisions tied to the approval. Guggenheim note
• Neutral Sentiment: Trading and options volumes are unusually high around the approval-driven move, amplifying short‑term swings and making intraday price moves less predictive of fundamentals. Options activity report
• Neutral Sentiment: Company commentary and analyst write‑ups are clarifying label scope and launch plans but have not yet produced concrete revenue reads — useful for modeling but not definitive for near‑term earnings. Company discussion
• Negative Sentiment: Significant insider selling occurred over the last two trading days (CEO, directors, CFO, CAO and others). Most sales were via Rule 10b5‑1 plans or to cover tax withholding, but the scale of disposals can intensify near‑term downward pressure and signal profit‑taking after the approval rally. Insider trades summary
• Negative Sentiment: Some analysts caution that elevated expectations and rapid estimate revisions may limit further upside near term; the stock could consolidate or retrace as investors re‑rate forward revenue assumptions. Zacks caution

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TVTX shares. Citigroup upped their price target on Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen lowered Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Wedbush upped their price target on Travere Therapeutics from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group upped their price target on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.50.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. State of Wyoming purchased a new stake in shares of Travere Therapeutics in the 4th quarter valued at $37,000. Torren Management LLC purchased a new stake in shares of Travere Therapeutics in the 4th quarter valued at $38,000. Comerica Bank raised its holdings in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after buying an additional 492 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after buying an additional 487 shares during the period. Finally, First Horizon Corp purchased a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $36,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.